Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for Ligand Pharmaceuticals (LGNYZ) over the last 16 years, with Q3 2025 value amounting to $106.7 million.

  • Ligand Pharmaceuticals' Long-Term Investments rose 45451.0% to $106.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.7 million, marking a year-over-year increase of 45451.0%. This contributed to the annual value of $10.9 million for FY2024, which is 7029.9% down from last year.
  • According to the latest figures from Q3 2025, Ligand Pharmaceuticals' Long-Term Investments is $106.7 million, which was up 45451.0% from $18.0 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Long-Term Investments high stood at $375.0 million for Q1 2021, and its period low was $3.0 million during Q4 2022.
  • For the 5-year period, Ligand Pharmaceuticals' Long-Term Investments averaged around $194.3 million, with its median value being $106.7 million (2025).
  • In the last 5 years, Ligand Pharmaceuticals' Long-Term Investments tumbled by 9920.0% in 2022 and then soared by 112420.0% in 2023.
  • Ligand Pharmaceuticals' Long-Term Investments (Quarter) stood at $375.0 million in 2021, then tumbled by 99.2% to $3.0 million in 2022, then skyrocketed by 1124.2% to $36.7 million in 2023, then tumbled by 70.3% to $10.9 million in 2024, then surged by 878.37% to $106.7 million in 2025.
  • Its Long-Term Investments stands at $106.7 million for Q3 2025, versus $18.0 million for Q2 2025 and $18.0 million for Q1 2025.